Experimental drug RMC-5552 tested in recurrent glioblastoma – early trial ends
NCT ID NCT05557292
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested the drug RMC-5552 in 7 adults with glioblastoma that had returned after standard treatment. The drug works by blocking a protein called mTOR, which may help stop cancer cells from growing. The study aimed to find the safest dose and check for side effects, but it was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RMC-5552 (a drug that blocks a protein called mTOR, which may slow cancer growth)
What this could lead to
If successful, this could point toward a new treatment option for recurrent glioblastoma, a difficult-to-treat brain cancer.
What could go wrong
This was a very early, small trial (only 7 people) that was terminated, so results are limited. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States